Table 2.
Pathology and oncologic outcomes
| Factor | Group; no. (%)* | p value | |
|---|---|---|---|
| HLAPD, n = 13 | OPD, n = 20 | ||
| Tumour size, cm | 3.5 (1.8–4.2) | 3.5 (1.5–6.5) | 0.71 |
| R1 resection margin | 3/10 (30) | 7/15 (47) | 0.68 |
| Lymph node harvest | 22 (14–56) | 20 (7–45) | 0.09 |
| Positive lymph nodes | 9 (69) | 9 (53) | 0.47 |
| Pathology | |||
| Malignant | 10 (77) | 15 (75) | — |
| Pancreatic adenocarcinoma | 9 | 11 | — |
| Ampullary adenocarcinoma | 1 | 3 | — |
| Neuroendocrine tumour | 0 | 1 | — |
| Benign | 3 (23) | 5 (25) | — |
| Intraductal papillary mucinous neoplasm | 1 | 3 | — |
| Duodenal polyp | 1 | 1 | — |
| Autoimmune pancreatitis | 1 | 0 | — |
| Perforated gastric ulcer | 0 | 1 | — |
HLAPD = hybrid laparoscopy-assisted pancreaticoduodenectomy; OPD = open pancreaticoduodenectomy
*
Unless otherwise indicated.